Orally active, selective vasopressin V1b receptor antagonist in vitro and in vivo.
SSR149415 is an orally active, selective vasopressin V1b receptor antagonist (human/rat Ki in nM = 1.5/1.3/V1b, 91/1050/V1a, 1412/2897/V2, 174/270/OT) that inhibits 30 nM AVP-induced Ca2+ response in human and rat V1b CHO transfectants (Ki = 1.26/2.0 nM). SSR149415 suppresses AVP-mediated physiological responses in vivo, including corticotropin secretion (1-30 mg/kg p.o. or i.p. in rats) upon exogenous AVP administration (0.3 µg/kg alone or 0.03 µg/kg with 0.1 µg corticoliberin/kg via i.v.), restraint stress-Induced corticotropin secretion (EC50 = 10 mg/kg i.p. in rats), and in a murine model of anxiety (four-plate test; 1-10 mg/kg i.p. or 3-10 mg/kg p.o. acute or 10 mg/kg/day p.o.).
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Faites votre choix parmi les versions les plus récentes :
Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus
Journal of Biomolecular Structure & Dynamics, 37(7), 1685-1699 (2019)
The role of the vasopressin system and dopamine D1 receptors in the effects of social housing condition on morphine reward
Drug and Alcohol Dependence, 188, 113-118 (2018)
Differential activation of arginine-vasopressin receptor subtypes in the amygdaloid modulation of anxiety in the rat by arginine-vasopressin
Psychopharmacology, 235(4), 1015-1027 (2018)
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Proceedings of the National Academy of Sciences of the USA, 99(9), 6370-6375 (2002)
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
Journal of Pharmacology and Experimental Therapeutics, 300(3), 1122-1130 (2002)
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
![[Arg8]-Vasopressin acetate salt ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/282/717/a4c16d4f-e168-4d84-a0e3-59de3e06251e/640/a4c16d4f-e168-4d84-a0e3-59de3e06251e.png)
